BetaInsiders sold $60.3M in the past 12 months.99.5% was sold under disclosed trading plans. The largest seller, Sanj Patel (Chairman & CEO, Director), sold $39.4M.Share-of-stake figures for this company are being verified and will be added when that check is finished. Why
Routine activity: 99.5% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.
A share of stake is shown for 0 of the 8 officers and directors who sold. 13 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Sanj Patel, Thomas Malley, Eben Tessari, John Paolini, Michael Megna, Mark Ragosa, Richard Levy, Ross Moat, Tracey McCain, Kimberly Popovits, Barry Quart, Bradley Cole and Dhiraj Malkani (share of stake is being verified).
Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.
Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
No officer or director trades were reported for the past 30 days. The most recent before that:
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Michael Megna Chief Accounting Officer | 4,600 | $80.30 | n/a | n/a | Sep 3, 2026 | Sep 3, 2026 |
BAKER BROS. ADVISORS LP reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.
Yes. Sanj Patel sold 822K shares ($39.4M) in the past 12 months, all of it under a trading plan disclosed in the filings.
Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 99.5% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 0.5% had no disclosed plan. A trading plan schedules sales in advance.
No. Officers and directors reported no purchases in the past 12 months.
| Who sold | Amount | % of holdings | Trading plan |
|---|---|---|---|
| Sanj Patel Chairman & CEO, Director | $39.4M 822K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| John Paolini Chief Medical Officer | $8.0M 181K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Mark Ragosa Chief Financial Officer | $5.6M 129K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Barry Quart Director | $2.7M 59K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Michael Megna Chief Accounting Officer | $2.6M 62K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Eben Tessari Chief Strategy Officer | $1.5M 37K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
| Bradley Cole Director | $299K 3.7K shares | Not confirmedshare of stake is being verified. Why | No plan disclosed |
| Ross Moat Chief Operating Officer | $195K 4.1K shares | Not confirmedshare of stake is being verified. Why | Disclosed plan |
Outside holder, reported separately: BAKER BROS. ADVISORS LP (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held |
|---|---|---|---|---|
Sanj Patel!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Sanj Patel are complete. Chairman & CEO, Director | n/a | −822K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Sanj PatelHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sanj Patel are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −45Kwithheld by the company for taxes | ||||
Thomas Malley!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Thomas Malley are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Thomas MalleyHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Thomas Malley are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Eben Tessari!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Eben Tessari are complete. Chief Strategy Officer | n/a | −37K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Eben TessariHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Eben Tessari are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −2.6Kwithheld by the company for taxes | ||||
John Paolini!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for John Paolini are complete. Chief Medical Officer | n/a | −181K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for John PaoliniHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Paolini are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −8.1Kwithheld by the company for taxes | ||||
Michael Megna!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michael Megna are complete. Chief Accounting Officer | n/a | −62K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Michael MegnaHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michael Megna are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −10Kwithheld by the company for taxes | ||||
Mark Ragosa!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Mark Ragosa are complete. Chief Financial Officer | n/a | −129K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Mark RagosaHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Mark Ragosa are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −8.2Kwithheld by the company for taxes | ||||
Richard Levy!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Richard Levy are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Richard LevyHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Richard Levy are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Ross Moat!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ross Moat are complete. Chief Operating Officer | n/a | −4.1K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Ross MoatHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ross Moat are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) −6.5Kwithheld by the company for taxes | ||||
Tracey McCain!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Tracey McCain are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Tracey McCainHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tracey McCain are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Kimberly Popovits!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Kimberly Popovits are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Kimberly PopovitsHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Kimberly Popovits are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Barry Quart!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Barry Quart are complete. Director | n/a | −59K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Barry QuartHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Barry Quart are complete; balances and unit counts will be added when the check is finished. −2.6Kgifted (net of own trusts) | ||||
Bradley Cole!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Bradley Cole are complete. Director | n/a | −3.7K | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Bradley ColeHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Bradley Cole are complete; balances and unit counts will be added when the check is finished. −4.5Kgifted (net of own trusts) | ||||
Dhiraj Malkani!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Dhiraj Malkani are complete. Chief Strategy Officer | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Dhiraj MalkaniHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Dhiraj Malkani are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Holdings and share of stake for Kiniksa Pharmaceuticals International, plc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Officer and director open-market sales: $60.3M across 1,297,958 shares. Plan status and stated purpose are separate questions, and a sale can have both.
The lighter segment is sales with no plan disclosed in the filing ($299K), including tax-related sales outside a plan.
Sales with no 10b5-1 plan and no tax reference in the filing. $299K of it is Bradley Cole. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Bradley Cole, Jul 29, 2026
81,198 shares ($5.4M) were withheld by the company for taxes, which isn't a market sale.
Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.
| Seller | Shares sold | Proceeds | Under a disclosed plan | Share of total | Sales dates |
|---|---|---|---|---|---|
| Sanj Patel Chairman & CEO, Director | 822K | $39.4M | 100% | 65% | Oct 20, 2025 to May 1, 2026 |
| John Paolini Chief Medical Officer | 181K | $8.0M | 100% | 13% | Oct 31, 2025 to May 1, 2026 |
| Mark Ragosa Chief Financial Officer | 129K | $5.6M | 100% | 9% | Oct 28, 2025 to Mar 9, 2026 |
| Barry Quart Director | 59K | $2.7M | 100% | 4% | Dec 15, 2025 to Apr 28, 2026 |
| Michael Megna Chief Accounting Officer | 62K | $2.6M | 100% | 4% | Oct 20, 2025 to Sep 3, 2026 |
| Eben Tessari Chief Strategy Officer | 37K | $1.5M | 100% | 2% | Oct 14, 2025 to Dec 15, 2025 |
| Bradley Cole Director | 3.7K | $299K | 0% | 0.5% | Jul 29, 2026 to Jul 29, 2026 |
| Ross Moat Chief Operating Officer | 4.1K | $195K | 100% | 0.3% | Apr 6, 2026 to Apr 9, 2026 |
| Month | Sale proceeds | Disclosed plan | To cover taxes | No plan disclosed |
|---|---|---|---|---|
| Oct 2025 | $15.5M | $15.5M | $0 | $0 |
| Nov 2025 | $1.3M | $1.3M | $0 | $0 |
| Dec 2025 | $3.1M | $3.1M | $0 | $0 |
| Jan 2026 | $503K | $503K | $0 | $0 |
| Feb 2026 | $1.6M | $1.6M | $0 | $0 |
| Mar 2026 | $3.5M | $3.5M | $0 | $0 |
| Apr 2026 | $28.3M | $28.3M | $0 | $0 |
| May 2026 | $5.8M | $5.8M | $0 | $0 |
| Jun 2026 | $0 | $0 | $0 | $0 |
| Jul 2026 | $299K | $0 | $0 | $299K |
| Aug 2026 | $0 | $0 | $0 | $0 |
| Sep 2026 | $369K | $369K | $0 | $0 |
| Oct 2026 | $0 | $0 | $0 | $0 |
More than usual: about 3x the 5-year average. 8 insiders sold; the average is 4 a year.
| 12 months ending | Shares sold | Insiders who sold | Proceeds |
|---|---|---|---|
| Oct 13, 2026 Latest 12 months | 1.30M | 8 | $60.3M |
| Oct 13, 2025 1 year earlier | 1.45M | 8 | $41.8M |
| Oct 13, 2024 2 years earlier | 541K | 6 | $12.9M |
| Oct 14, 2023 3 years earlier | 80K | 2 | $1.3M |
| Oct 14, 2022 4 years earlier | 0 | 0 | $0 |
| Oct 14, 2021 5 years earlier | 59K | 2 | $1.3M |
Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Kiniksa Pharmaceuticals International, plc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 378 Forms 3, 4 and 5 on record for Kiniksa Pharmaceuticals International, plc (SEC CIK 1730430), filed from May 23, 2018 to Sep 3, 2026; 57 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
| Name | Last filed | Last reported balance |
|---|---|---|
| Arian Pano | Sep 7, 2021 | 1,539 shares, last reported balance as of Jun 10, 2021 |
| Thomas Beetham | Mar 23, 2021 | 411,680 shares, last reported balance as of Feb 3, 2021 |
| Qasim Rizvi | Jan 5, 2021 | 35,176 shares, last reported balance as of Dec 31, 2020 |
| Chris Heberlig | Sep 19, 2019 | 520,509 shares, last reported balance as of May 29, 2018 |
| Stephen Mahoney | Sep 19, 2019 | 772,214 shares, last reported balance as of May 29, 2018 |
| Cormorant Asset Management, LP | May 31, 2018 | 1,731,442 shares, last reported balance as of May 29, 2018 |
| James Flynn | May 31, 2018 | 1,226,890 shares, last reported balance as of May 29, 2018 |
| Carsten Boess | May 29, 2018 | 552,624 shares, last reported balance as of May 29, 2018 |
| Stephen Biggar | No balance on record | |
| Meta Boyd | No balance on record |
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.